Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Unknown 2Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5Thoracic 2Gynecologic 2Gastrointestinal 2Sarcoma 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Colorectal Neoplasms 105Carcinoma, Hepatocellular 34Neoplasm Metastasis 19Neoplasms 17Gastrointestinal Stromal Tumors 17Colonic Neoplasms 14Rectal Neoplasms 12Liver Neoplasms 8Glioblastoma 7Sarcoma 6Stomach Neoplasms 5Sarcoma, Ewing 5Ovarian Neoplasms 5Osteosarcoma 5Melanoma 5Cholangiocarcinoma 5Adenocarcinoma 5Pancreatic Neoplasms 4Esophageal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Small Cell Lung Carcinoma 3Rhabdomyosarcoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Leukemia, Myeloid, Acute 3Colorectal Cancer Metastatic 3Carcinoma, Transitional Cell 3Carcinoma 3Advanced Colorectal Cancer 3Thyroid Neoplasms 2

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Specimen Handling 36Cisplatin 36CTLA-4 Antigen 36Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Melanoma × regorafenib × Clear all
NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT05370807 2023-10-24

RegoMel

Universitair Ziekenhuis Brussel

Phase 2 Unknown
48 enrolled
Dermatologic

Melanoma

NCT02307500 2022-09-10

RESOUND

Istituto Clinico Humanitas

Phase 2 Completed
82 enrolled
DermatologicGastrointestinalGynecologicSarcomaThoracic

Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Thymoma

NCT02501551 2021-04-05

Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy

Yonsei University

Phase 2 Unknown
36 enrolled
Dermatologic

Melanoma

NCT02587650 2020-01-27

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

University of California, San Francisco

Phase 2 Terminated
1 enrolled 7 charts
Dermatologic

Noonan Syndrome 6, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡